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Although monosodium glutamate (MSG) is classified as a causative substance of headache in the International
Classification of Headache Disorders 3rd edition (ICHD-III beta), there is no literature in which causal relationship
between MSG and headache was comprehensively reviewed. We performed systematic review of human studies
which include the incidence of headache after an oral administration of MSG. An analysis was made by separating
the human studies with MSG administration with or without food, because of the significant difference of kinetics
of glutamate between those conditions (Am J Clin Nutr 37:194–200, 1983; J Nutr 130:1002S–1004S, 2000) and there
are some papers which report the difference of the manifestation of symptoms after MSG ingestion with or without
food (Food Chem Toxicol 31:1019–1035, 1993; J Nutr 125:2891S-2906S, 1995). Of five papers including six studies
with food, none showed a significant difference in the incidence of headache except for the female group in one
study. Of five papers including seven studies without food, four studies showed a significant difference. Many of
the studies involved administration of MSG in solution at high concentrations (>2 %). Since the distinctive MSG is
readily identified at such concentrations, these studies were thought not to be properly blinded. Because of the
absence of proper blinding, and the inconsistency of the findings, we conclude that further studies are required to
evaluate whether or not a causal relationship exists between MSG ingestion and headache.
Keywords: Monosodium glutamate (MSG), Headache, International classification of headache disorders (ICHD),
Systematic review, Human study, Chinese restaurant syndrome (CRS)Background
Monosodium glutamate is used worldwide as a flavor
enhancer. So called Chinese restaurant Syndrome (CRS)
was first reported by Kwok in 1968 [1]. He reported that
after consumption of Chinese dishes, some transient
subjective symptoms occurred such as numbness, general
weakness, palpitation, etc. Although many human studies
were conducted afterwards to determine if a causal
relationship occurs between MSG and this symptom
complex, the results were inconsistent. Headache was
reported to be one of this symptom complex.
The safety of glutamic acid and its salts as flavor
enhancers was evaluated by the Joint FAO/WHO Expert
Committee on Food Additives in 1971 [2], 1974 [3], and* Correspondence: obayashiy@ajiusa.com
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reproduction in any medium, provided you giv
the Creative Commons license, and indicate if1987 [4] and it allocated an “acceptable daily intake
(ADI) not specified” based on the conclusion that the
total intake of glutamate arising from their use at levels
necessary to achieve the desired technological effect and
from their acceptable background in food do not repre-
sent a hazard to health.
In this review, we report the results of a systematic
review of available human studies of MSG, focusing on
the causal relationship between MSG intake and head-
ache by separate analysis of the studies with MSG
administration with or without food. We also discuss the
scientific validation of ICHD-III beta on MSG [5], based
on our review of the studies cited.Review
Methods
Since most of the human studies that include data on
the headache incidence focus on symptom complex ands This article is distributed under the terms of the Creative Commons Attribution
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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was optimized to obtain as many human study data with
MSG administration as possible.
The literature search was conducted on Medline and
FSTA. Initially, we searched for titles that includes any of
the following terms: “monosodium glutamate”, “MSG”,
“monosodium L-glutamate”, “sodium glutamate”, and
“sodium L-glutamate”. In case of Medline, the search was
narrowed down by specifying article type as “clinical trial”.
The above search result was further narrowed down by the
following conditions; (1) the paper is written in English, (2)
the paper is a human study with the administration of
MSG using healthy adults, (3) the incidence of headache is
shown, and (4) a statistical analysis was performed on the
incidence of headache, or the paper includes sufficient data
with which to perform statistical analysis.
Results and discussion
Result of the literature search
The literature search identified eight human studies
using Medline and two human studies using FSTA that
met our inclusion criteria. Of these ten papers, five papers
were the human studies with the MSG administra-
tion with food and the dose of MSG was 1.5 –
3.15 g [6–10]. The other five papers were the studies
with the MSG administration without food and the
dose of MSG was 1.25 – 12 g [11–15]. The outline
of these studies is shown in Tables 1 and 2. ICHD-
III beta referenced five papers concerning MSG in
section 8.1 [6, 12, 16–18]. The outline of these pa-
pers is shown in Tables 3 and 4.
Blind integrity
The normal content of added MSG in food is 0.2–0.8 %
for appropriate taste. Kenny reported that the subjects
responded favorably in terms of taste and palatability of
tomato juice containing 1 g MSG in 150 ml and less
favorably when larger quantities (>2 g) were given [17]. In
addition, Gore reported that there were statistically signifi-
cant difference between the taste and after taste of 1–4 %
MSG dissolved in water compared with placebo solution
[16]. It is also reported that high dose of MSG causes vari-
ous adverse gastrointestinal reactions, leading to vomiting
at very high dose [19]. Taken together, it can be assumed
that the beverage containing 1.3 % MSG (2 g/150 ml-) or
more should be distinguishable from placebo beverage
and have an unfavorable taste.
Therefore, we analyzed the human studies, especially pay-
ing attention to the blind integrity and validity of the data.
Human studies with MSG administration with food
Regarding the studies with the MSG administration with
food, five papers which include six studies were found
(Table 1).On the study reported by Praworphardjono [7] and at
the first stage of Tarasoff ’s study [6], 1.5, 3.0 g MSG or
placebo in capsules was administered in fasted condi-
tions, followed by the ingestion of a standardized break-
fast. At the second stage of Tafasoff”s study, the subjects
ingested a specially formulated soft drink which included
3.15 g MSG or placebo, and then consumed the stan-
dardized breakfast. Although at this second stage, some
subjects might be able to distinguish placebo and MSG
beverage, they analyzed only the data from 61 subjects,
who reported no after-taste, out of 71 subjects. In all
studies by Praworphardjono and Tarasoff, no difference
of incidence of headache between placebo and MSG
administration was found and the authors concluded
that rigorous and realistic scientific evidence linking
CRS to MSG could not be found.
Tanphaichitr investigated the incidence of unpleasant
symptoms after ingestion of a breakfast containing
added MSG or no added MSG [8]. In the first experi-
ment, using ten subjects, a menu that masked the taste
of MSG was identified. Four menus without MSG and
one menu with 3 g MSG were served to 50 subjects as a
breakfast on day 1–5 one-by-one. No one served with
the menu containing MSG had a headache and the
author concluded that the addition of MSG did not
cause significant difference in unpleasant symptoms of
CRS from those on menu without MSG.
Thus, those three studies above can be thought properly
blinded, but the following two studies reported by Zanda
[9] and Morselli [10] might not ensure the sufficient blind
integrity. In both studies, 3 g MSG in 150 ml beef broth
(2 %) was administered followed by other dishes. No sig-
nificant difference in the incidence of CRS symptoms was
found in both studies, with the exception of headache oc-
currence among females in Zanda’s study: an incidence in
6 subjects was observed on the MSG day, but only 1 on
the placebo day (P < 0.05). Clinically meaningful differ-
ences in objective indices, such as arterial blood pressure
and pulse rate, were not observed. In total 73 subjects (38
males, 35 females) joined this study. We note that the
number of migrainers is higher in females than in males
(France; male 6.35 %, female 15.7 %, USA; male 6.6 %,
female 19.2 %) [20], and unpleasant taste and unfavorable
sensation caused by high dose of MSG may become a
stimulant to trigger headache on migrainers especially
when they are fasted. Placebo effect by distinguishable
taste also should not be ignored.
In the study by Morselli, they concluded that no differ-
ence in all CRS symptoms including headache between
the subjects given MSG and control broth.
Human studies with MSG administration without food
Regarding the studies of MSG administration without
food, we found five papers containing seven studies
Table 1 Human studies of MSG with food
First author Vehicle for MSG
administration
Protocol Number of subjects Incidence of headache Statistical difference
Prawirohardjono
W (2000) [7]
Opaque capsule (1)In the morning, after fasting
for 10 h, subjects ingested three
capsules containing MSG(0.5 g
MSG & 0.5 g lactose or 1.0 g
MSG) or placebo(1.0 g lactose).




52 healthy volunteers (Indonesians)
(Mean age 29.6 ± 6.5y, mean mass
53.4 ± 7.4 kg, mean height 159.9 ±
7.7 cm) *No indication about gender.
Placebo : 3
1.5 g MSG : 4
3.0 g MSG : 2
No difference
Tarasoff L (1993) [6] Capsule Fasting condition
On first 3 days, 6 capsules
immediately followed by
breakfast.
71 healthy volunteers (female:41,
mean age:30.7)
*Mainly Caucasians
Placebo (gelatin powder): 1
1.5 g MSG: 0




On remaining 2 days, 300 ml soft
drink immediately followed by
breakfast.
Placebo (drink): 0




Boiled rice with pork Menu A-D(w/o MSG), E(added
3 g MSG) were serve as breakfast
on Day 1–5 by this order.




Menu E(3 g MSG):0
No difference
Zanda G (1973) [9] Beef bouillon 3 g MSG(placebo: no MSG, no
substitute) in 150 ml beef
bouillon followed by other
dishes.
[First session] Some subjects at
random received MSG.
[Second session(2 days later)]
Opposite to the first session
73 healthy volunteers (male:38,
female:35, mean age:25, 17–76y)
Control(male):1
Control(female):1
3 g MSG (male):1
3 g MSG (female):6* (P < 0.05)
Responded to both (male):2







Blood pressure and pulse rate
were also recorded.
Morselli PL (1970) [10] Beef broth 3 g MSG in 150 ml beef broth
followed by other dishes(meat,
vegetables, fruit).
[First session] MSG:8 sub.,
control:16 sub.
[Second session(2 days later)]
Opposite to the first session
24 healthy volunteers (male:17,
female:7)
Control: 1
3 g MSG: 2
No difference

















Table 2 Human studies of MSG without food
Researcher Vehicle for MSG
administration
Protocol Number of subjects Incidence of headache Statistical difference
Geha RS (2000) [11] 200 ml of citrus-
flavored beverage
[Protocol A]
5 g MSG and placebo (0 g MSG)





5 g MSG: 0.54 (P < 0.005)**
Significant difference




(1) 5 g MSG or placebo(0 g MSG)
(empty stomach)
61 subjects self-identified MSG-
sensitive people (male:15, white:59,
black:1, oriental:1)
Placebo: 24
5 g MSG: 23
No difference
(2) placebo(0 g MSG, no
substitute), 1.25, 2.5, 5 g MSG in
random sequence.
36 subjects Subjects who responded
to either of MSG or placebo in
study(1) (not both or not neither).
No indication about gender.
Placebo: 9
1.25 g MSG: 11
2.5 g MSG:16(P < 0.04)*
5 g MSG: 18(P < 0.023)*
1.25 g: no difference
2.5, 5 g:significant
difference
Shimada A (2013) [13] 400 ml Sugar-free
lemon soda
MSG (150 mg/kg = 9 g/60 kg) for
5 consecutive days (in the week)
and NaCl (24 mg/kg) in the other
week in randomized sequence.
14 healthy adults (female:9, male:5) Placebo: 2
150 mg/kg MSG(=9 g/60 kg): 8*
(P = 0.041)
Significant difference
Baad-Hansen L (2010) [14] 400 ml Sugar-free
soda
NaCl (24 mg/kg), MSG (75 or
150 mg/kg =6 or 9 g/60 kg) in
random sequence.
14 healthy men Placebo: 0
75 mg/kg MSG(=4.5 g/60 kg): 27*
(P = 0.045, vs placebo and
150 mg/kg MSG)
150 mg/kg MSG (=9 g/60 kg): 7
75 mg/kg: significant
difference 150 mg/kg: no
difference
Rosenblum I (1971) [15] 100 ml tap water or
chicken stock
15 h after the last meal.
(Group I–IV)5 g MSG in tap
water(49 subjects) or chicken
stock(49 sub.).
(Group V)1.7 g NaCl in chicken
stock(24 sub.)
(Group VI) chicken stock(25 sub.).
99 male volunteers, 21–59 years old. [Frequency]
Placebo(Group V, VI):8 %
5 g MSG(Group I–IV):17 %
No difference
100 ml chicken stock (Group VII) 8 g(6 sub.) MSG in
chicken stock, 2.8 g NaCl in
chicken stock(5 sub.).
(Group VIII) 12 g MSG in chicken
stock(5 sub.), 4.2 g NaCl in
chicken stock (5 sub).
11 people Chosen from the original
99 subjects, based on the results of
the test above. One-half reported
multiple complaints on the







*; Statistically significant difference was found between placebo and MSG group (P < 0.05)

















Table 3 Human studies of MSG which were referenced by ICHD-III beta
First author study type Number of
subjects








human study 71 capsule w performed No difference





5 g MSG/200 ml strongly
citrus-tasting beverage
w/o performed No difference
36(self-identified
MSG sensitive)
1.25–5 g MSG/200 ml strongly
citrus-tasting beverage








human study 77 5 g MSG/150 ml tomato juice w/o not performed No difference
(Fisher test)
22 1–5 g MSG/ 150 ml tomato
juice or water
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beverage or soup at relatively high concentrations (1.125 –
12 %) was administered to the subjects.
A statistical difference of incidence of headache was
reported in four out of seven studies. In two of those
four studies reported by Geha [11] and Yang [12],
self-identified MSG sensitive subjects were recruited
and 200 ml of a citrus-flavored beverage with or
without MSG was administered to 130 and 36Table 4 Human studies of MSG which were referenced by ICHD-III b
review







After an overnight fast,
subjects ingested, on different
days, 1.5, 3, 6 g MSG and three
paired placebo materials, the
order of each pair being
randomized. (There was no









2 h after breakfast, 5 g MSG
















JP1 : 0.8 g NaCl, WP: 0.7 g
NaCl,
WM5 : 5 g MSG + 0.2 g NaCl,
JM1 : 1 g MSG, JM2 : 2 g MSG,
JM3 : 3 g MSG, JM4 : 4 g MSG,




MSG onsubjects, respectively. In Geha’s study, the dose of
MSG was 5 g (2.5 %) and the significant difference of
incidence of headache in MSG group was found.
Yang’s study was composed of two studies and the
first study did not show statistical difference, despite
of a large amount of MSG, i.e. 5 g (2.5 %), ingested.
However, at the second stage, in which the subjects
reacted to either of MSG or placebo at the first stage
joined, a significant difference in the incidence ofeta but were not complied with the criteria for the systematic
of subjects Incidence of headache Statistical difference
25 women [Total number of positive
responses by 3 doses]





Statistical analysis in each
symptom was not
performed in the paper.
) 77 [Number of positive
responses]
MSG : 4, Placebo : 2
No difference
(Fisher test)
Statistical analysis was not







JM1 : 1 /15, JM2 : 2/13,
JM3 : 4/13, JM4 : 5/14,
WM5 : 8/17
Since the incidence of
placebo group (JP1, WP,
JP2) is not shown,
statistical analysis cannot
be done.
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2.5 %) and the dose dependency was reported.
Among three other studies using subjects who were
not restricted to self-identified MSG sensitive subjects, a
significant difference in the incidence of headache was
found in two studies, both of which originated in the
same laboratory in Denmark [13, 14]. In the first study
reported by Baad-Hansen, 400 ml sugar-free soda con-
taining MSG (75 or 150 mg/kg) or NaCl (24 mg/kg) was
administered to 14 healthy men [14]. These doses
correspond to 4.5 g (1.125 %) and 9.0 g (2.25 %) /400 ml・
60 kg b.w., respectively. A significant difference in the inci-
dence of headache was observed at the 75 mg/kg dose of
MSG, but not at the 150 mg/kg dose compared to the
NaCl placebo. In the second study reported by Shimada,
the protocol and the number of subjects were the same as
in the first study, except that the number of days in one
session was increased from 1 to 5 days to amplify the inci-
dence and the MSG dose was 150 mg/kg, along with the
placebo 24 mg/kg NaCl [13]. During one session, either of
MSG or NaCl was administered. The 400 ml volume and
the high dose of MSG, especially 150 mg/kg, are thought
to be sufficient to cause gastrointestinal unpleasant sen-
sation attributable to unfavorable taste and high os-
motic pressure. The other issue of these studies are that
the content of sodium in placebo (24 mg/kg) corre-
sponds to 75 mg/kg MSG and half of 150 mg/kg MSG.
It means that the saltiness and osmotic pressure caused
by placebo solution was much less than MSG solution
of 150 mg/kg dose. In addition, the number of 14 sub-
jects is too small to permit any conclusion regarding
large population.
On the other hand, in Rosenblum’s study using 99
male subjects, 5, 8, 12 g MSG (5, 8, 12 %) and osmotic-
ally equivalent dose of NaCl dissolved in 100 ml tap
water or chicken stock was administered [15]. A signifi-
cant difference in the incidence of headache was not
observed at any dose.
Thus, the results of those studies are inconsistent and
it is difficult to conclude whether MSG ingestion with-
out food causes headache. The effect of blind integrity
seems to be more influential to self-identified MSG-
sensitive subjects.
Human studies which were cited by ICHD-III beta
Among the five papers cited (Table 3), two complied
with our search criteria, and are discussed above [2, 11].
The other two human study papers which did not com-
ply with our search criteria were authored by Gore and
Kenny, respectively (Table 4) [16, 17]. Gore’s paper does
not contain the term meaning “monosodium-L-glutamate”
in the title, and in Kenny’s paper, the statistical analysis
could not be performed due to a lack of placebo data.
Statistical analysis was not performed in either papers.The remaining one paper by Meritt was an in vitro
study [18].
Gore et al. reported the study using 55 subjects. They
ingested 1.5, 3, 6 g MSG and three paired placebo mate-
rials dissolved in 150 ml cold tap water on different days
[16]. The incidence of headache was shown as a total
number of incidences by three doses, which did not
show statistical difference according to our analysis.
In the study reported by Kenny et al., MSG-reactors
were screened from 77 subjects at the first study by the
administration of 150 ml tomato juice with 5 g MSG or
0.8 g NaCl [17]. According to our analysis, a statistical
difference in the incidence of headache was not ob-
served in the first study. Twenty-two MSG-reactors,
who suffered from any symptoms in the first study,
formed test groups in the second study and were admin-
istered 1–5 g MSG dissolved in 150 ml tomato juice or
water. We could not perform a statistical analysis on the
results, due to a lack of placebo data.
Among above-mentioned four papers on human studies,
consisting of six studies, a statistical difference was found
only in one study reported at the second stage of Yang’s
study, which is aforementioned.
The in vitro study authored by Merrit focused on a
direct effect of MSG on contraction and relaxation of
rabbit aorta. However, we should pay attention to the lit-
tle impact of MSG ingestion on plasma glutamate level,
especially when MSG is ingested with food as a flavor
enhancer [21]. Tsai et al. reported the circadian variation
of plasma glutamate level when the meals added
100 mg/kg MSG (15, 40, 45 mg/kg to breakfast, lunch
and dinner) were given to healthy adult men. It ranged
between 33 and 48 μmol/l on days without added MSG,
and 32 and 53 μmol/l on days with added MSG [22]. Al-
though 100 mg/kg MSG (6 g MSG/60 kg bw) is much
larger dose than the average MSG intake from food (es-
timated intake of added glutamate is c.a. 0.4 g in Europe
and 1.2–1.7 g in Asian countries [23]), about 10 %
change of circadian variation can be regarded as being
within the rage of daily variation.
Taken together, it is difficult to argue from this group
of studies that MSG causes headache.
Conclusion
Among human studies with the MSG administration
with food, significant difference of headache incidence
was not found at the dose of 1.5 and 3.0 g in capsule,
3.15 g/300 ml beverage, 3.0 g in boiled rice with pork,
and 3.0 g/150 ml beef broth. The significant difference
was found only in female administered 3.0 g MSG/
150 ml (2.0 %) beef bouillon but not in male.
In all the studies with MSG administration without
food, MSG was administered, being dissolved in beverages
Obayashi and Nagamura The Journal of Headache and Pain  (2016) 17:54 Page 7 of 7or soup at relatively high concentrations (1.125–12 %). In
those studies, significant difference of headache incidence
was found at the dose of 2.5 g/200 ml, 5.0 g/200 ml, 6 g/
400 ml・60 kg bw, 9 g/400 ml・60 kg bw, but not found
at 1.25 g/200 ml, 5.0 g/200 ml, 9 g/400 ml・60 kg bw,
5.0 g/100 ml, 8.0 g/100 ml, 12.0 g/100 ml.
We should pay attention to the blind integrity of the
human studies where high dose of MSG was adminis-
tered in solution, especially focusing on the distinguish-
able and unpleasant taste of MSG solutions at 1.3 %
(2 g/150 ml) or more and the gastrointestinal discom-
fort caused by high dose of MSG. These events may
influence the occurrence of headache quite strongly
especially in case of migrainers and the subjects who
believe they are MSG-sensitive.
From the fact that the results of the human studies are
not consistent and it is assumed that most studies using
beverages as a vehicle are not properly blinded, we
suggest that a causal relationship between MSG and
headache has not been proven. In addition, statistically
significant differences in the incidence of headache were
not observed when MSG was administered with food,
except in one case of the female group where the blind
integrity was questionable. It would seem premature to
conclude that the MSG present in food causes headache.
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